Clinical & Translational Oncology最新文献_第7页

A prognostic model constructed by ferroptosis-associated genes (FAGs) in papillary renal cell carcinoma (PRCC) and its association with tumor mutation burden (TMB) and immune infiltration. 通过乳头状肾细胞癌（PRCC）中的铁突变相关基因（FAGs）构建的预后模型及其与肿瘤突变负荷（TMB）和免疫浸润的关系。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-16 DOI: 10.1007/s12094-024-03617-y

Yong-Bo Chen, Xin Yang, Dong Lv, Liang-You Tang, Ying-Wen Liu

{"title":"A prognostic model constructed by ferroptosis-associated genes (FAGs) in papillary renal cell carcinoma (PRCC) and its association with tumor mutation burden (TMB) and immune infiltration.","authors":"Yong-Bo Chen, Xin Yang, Dong Lv, Liang-You Tang, Ying-Wen Liu","doi":"10.1007/s12094-024-03617-y","DOIUrl":"10.1007/s12094-024-03617-y","url":null,"abstract":"Background: This study aimed to identify the prognostic-related differentially expressed ferroptosis-associated genes (DEFAGs) in papillary renal cell carcinoma (PRCC).Methods: Data encompassing simple nucleotide variation, transcriptome profiles, and relevant clinical information of PRCC patients were sourced from The Cancer Genome Atlas (TCGA) database. The expression matrix of ferroptosis-associated genes (FAGs) was analyzed using the \"limma\" package in R to identify differentially expressed DEFAGs. Lasso regression analysis, along with univariate and multivariate Cox proportional hazards regressions, was employed to identify independent prognostic-related DEFAGs and formulate a nomogram. Additionally, we examined potential independent survival-related clinical risk factors and compared immune cell infiltration and tumor mutation burden (TMB) differences between high- and low-risk patient groups.Results: A cohort of 321 patients were analyzed, revealing twelve FAGs significantly influencing the overall survival (OS) of PRCC patients. Among them, two mRNAs (GCLC, HSBP1) emerged as independent prognostic-related DEFAGs. Smoking status, tumor stage, and risk score were identified as independent clinical risk factors for PRCC. Furthermore, notable disparities in immune cell infiltration and function were observed between high- and low-risk groups. GCLC and HSBP1 were associated with various immune cells and functions, TMB, and immune evasion.Conclusion: This finding revealed two independent prognostic-related DEFAGs in PRCC and established a robust prognostic model, offering potential therapeutic targets and promising insights for the management of this disease.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1232-1247"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of the doctor-nurse-patient workshop transitional care model on the post-operative quality of life of patients with laryngeal cancer. 医生-护士-患者工作坊过渡护理模式对喉癌患者术后生活质量的影响。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-07 DOI: 10.1007/s12094-024-03648-5

Su-Qing Chen, Jia-Lu Song, Hong Zhang

{"title":"The impact of the doctor-nurse-patient workshop transitional care model on the post-operative quality of life of patients with laryngeal cancer.","authors":"Su-Qing Chen, Jia-Lu Song, Hong Zhang","doi":"10.1007/s12094-024-03648-5","DOIUrl":"10.1007/s12094-024-03648-5","url":null,"abstract":"Objective: The aim of this study is to assess the efficacy of the doctor-nurse-patient workshop transitional care model on post-operative care for patients with laryngeal cancer and its influence on quality of life.Methods: A total of 68 patients with laryngeal cancer who underwent surgical treatment at the hospital between 2021 and 2022 were included in the study. The patients were divided into two groups, a control group and a research group, each consisting of 34 patients, based on the chronological sequence of their surgeries. Patients in the control group received standard nursing care, while those in the research group received the doctor-nurse-patient workshop transitional care model in addition to standard nursing care. After 2 months of care, levels of albumin (ALB), total protein (TP), hemoglobin (Hb), and quality of life scores (measured using the Quality of Life Instrument for Head and Neck Cancer, QLICP-HN) were compared between the two groups. Additionally, the incidence of adverse events during the recovery period was assessed and compared between the two groups.Results: Following 2 months of care, patients in the research group exhibited elevated ALB, TP, and Hb levels compared to those in the control group. Additionally, the average QLICP-HN scores were higher in the research group, while the incidence of adverse events was lower compared to the control group.Conclusion: Implementing the doctor-nurse-patient workshop transitional care model in home care for patients with laryngeal cancer can enhance their nutritional status post-surgery and improve their quality of life during home rehabilitation. This, in turn, leads to a reduction in the incidence of adverse events and complications during the recovery period.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1329-1333"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study. 西班牙转移性结直肠癌患者使用瑞戈非尼的实际剂量模式：RE-SEARCH 研究。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-11 DOI: 10.1007/s12094-024-03630-1

Ana María López Muñoz, Encarnación González Flores, Alberto Carral Maseda, Paola Pimentel Cáceres, Ruth Afonso Gómez, Carlos López López, Raquel Jimeno Maté, Juan José Reina Zoilo, Carmen Castañón López, Mercedes Salgado Fernández, Jorge Aparicio Urtasun, Elena Asensio Martínez, Teresa Martín Gómez

{"title":"Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study.","authors":"Ana María López Muñoz, Encarnación González Flores, Alberto Carral Maseda, Paola Pimentel Cáceres, Ruth Afonso Gómez, Carlos López López, Raquel Jimeno Maté, Juan José Reina Zoilo, Carmen Castañón López, Mercedes Salgado Fernández, Jorge Aparicio Urtasun, Elena Asensio Martínez, Teresa Martín Gómez","doi":"10.1007/s12094-024-03630-1","DOIUrl":"10.1007/s12094-024-03630-1","url":null,"abstract":"Purpose: To describe the dosing patterns of regorafenib in a real-world population of patients with metastatic colorectal cancer (mCRC) in a routine clinical practice setting in Spain, focusing on the starting dose of regorafenib.Methods: An observational, retrospective, multicenter study that included patients ≥ 18 years old who had histologically documented mCRC and who had initiated treatment with regorafenib since January 2017. Post hoc categorization of dosing patterns revealed the following: initial dose < 160 mg and dose escalation, initial dose < 160 mg and maintenance, initial dose equal to 160 mg and maintenance, and initial dose equal to 160 mg and dose reduction.Results: Most patients (152/241, 63.8%) initiated treatment with regorafenib at doses < 160 mg. There was large variation in the starting dose of regorafenib over time: in 2017, most patients (59%) initiated regorafenib at a dose of 160 mg, this proportion decreased to 6% in 2021. There were no significant differences in the median progression-free survival according to the regorafenib dose patterns during the first two cycles. The proportion of patients who reported at least one adverse event (AE), had a grade 3-4 AE or had an AE leading to dose reduction was greater in the group of patients who received an initial dose equal to 160 and reduction.Conclusions: Our results indicate that physicians in Spain have gradually adopted a dose-escalation approach during cycle 1, which is a common practice for starting treatment with a reduced dose (< 160 mg/day), a strategy that seems to improve tolerability while maintaining efficacy.Trial registration: Not applicable.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1176-1184"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis. 磷酸肌酸 3- 激酶抑制剂在晚期乳腺癌中的意义：系统综述和荟萃分析。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-10 DOI: 10.1007/s12094-024-03629-8

Asma Naqi, Mohammad Ahmed Khan, Abul Kalam Najmi

{"title":"Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis.","authors":"Asma Naqi, Mohammad Ahmed Khan, Abul Kalam Najmi","doi":"10.1007/s12094-024-03629-8","DOIUrl":"10.1007/s12094-024-03629-8","url":null,"abstract":"Background: The Phosphoinositide 3-kinase (PI3K) inhibitors may be used in cancer progression and mortality along with standard therapy to improve therapeutic efficacy of Advanced Breast Cancer (ABC).Purpose: This systematic review and meta- analysis were conducted to understand the therapeutic and toxicity profile of PI3K inhibitors in ABC.Methods: The electronic databases were searched for suitable trials as per the criteria. The outcomes assessed were Progression- Free Survival, Objective Response Rate and Disease Control Rate. The data were systematically reviewed and meta-analyzed by Mantele- Haenszel method.Results: Seven studies were included in the systematic review and meta- analysis. The co- administration of PI3K inhibitors with standard therapy improved the Progression- Free Survival significantly, while a marginal improvement was observed in Objective Response Rate, no difference in Disease Control Rate and toxicity significantly increased.Conclusions: The addition of PI3K inhibitors decreased the risk of progression but increased the risk of toxicity.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"950-959"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. 肿瘤浸润淋巴细胞与接受新辅助化疗的三阴性乳腺癌患者临床预后的关系：系统综述和荟萃分析。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-18 DOI: 10.1007/s12094-024-03661-8

Francisco Cezar Aquino de Moraes, Maria Eduarda Cavalcanti Souza, Vitor Kendi Tsuchiya Sano, Rachel Arantes Moraes, Ana C Melo

{"title":"Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Maria Eduarda Cavalcanti Souza, Vitor Kendi Tsuchiya Sano, Rachel Arantes Moraes, Ana C Melo","doi":"10.1007/s12094-024-03661-8","DOIUrl":"10.1007/s12094-024-03661-8","url":null,"abstract":"Objective: Triple-negative breast cancer (TNBC) presents a clinical challenge as an aggressive tumor, correlated with unfavorable prognosis. Tumor-infiltrating lymphocytes (TILs) have garnered interest as a potential prognostic biomarker. However, the disparity in outcomes between varying TILs rates remains inadequately explored.Methods: PubMed, Scopus, Web of Science, and Cochrane databases were searched for studies about the prognostic value of TILs in patients with TNBC receiving neoadjuvant chemotherapy. The hazard ratios (HRs) or odds ratios (ORs) were computed for binary endpoints, with 95% confidence intervals (CIs).Results: Twenty-nine studies were included, involving a population of six thousand one hundred sixty-one (80.41%) with TNBC. The cut-off TILs value ranged from 10 to 60%, with 50% being the most related value. Compared with the low-TIL expression group, the disease-free survival (DFS) (HR 0.71; 95% CI 0.61-0.82; p < 0.00001) and overall survival (OS) (HR 0.76; 95% CI 0.63-0.90; p = 0.002) rates showed significant improvement with higher TIL infiltrations. In the subgroup analyses of the lymphocyte subtypes CD4 + and CD8 + , there was statistical significance favoring higher TILs rates in both subtypes, each associated with improved DFS (HR 0.48; 95% CI 0.33-0.71; p = 0.0002) and OS (HR 0.53; 95% CI 0.36-0.78; p = 0.001), regardless of which cell subtype was predominantly infiltrated. The complete pathological response analysis showed better rates for the higher TIL group than the control for both the TIL (OR 1.29; 95% CI 1.13-1.48; p = 0.0003) and Ki-67 (OR 2.74; 95% CI 2.01-3.73; p < 0.00001) analyses.Conclusion: Higher expressions of TILs in patients with TNBC were associated with improved significantly DFS, OS, and pCR outcomes.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"974-987"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantitative parameters of HRCT target scan to predict the risk of lung adenocarcinoma based on the detection of lung ground-glass nodules. 基于肺磨玻璃结节检测的 HRCT 靶向扫描定量参数预测肺腺癌风险。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-24 DOI: 10.1007/s12094-024-03676-1

Jingfang Zhang, Peili Peng

{"title":"Quantitative parameters of HRCT target scan to predict the risk of lung adenocarcinoma based on the detection of lung ground-glass nodules.","authors":"Jingfang Zhang, Peili Peng","doi":"10.1007/s12094-024-03676-1","DOIUrl":"10.1007/s12094-024-03676-1","url":null,"abstract":"Background: To explore the value of high-resolution computed tomography (HRCT) in the differential diagnosis of benign and malignant ground-glass nodules (GGNs), and to provide a theoretical basis for the clinical application of HRCT.Methods: A total of 208 patients with GGN who had been clinically confirmed by surgical pathology and clinical confirmation were collected, and HRCT target scanning technology was used to scan and collect general information of patients, and observe the distribution of GGN, GGN size, GGN cross-sectional area, diameter, transverse diameter, solid composition, relationship with bronchi, and relationship with blood vessels and other indicators. Multivariate regression analysis and risk factor prediction are performed.Results: The differences were statistically significant in multivariate regression analysis, such as nodule location, maximum diameter, maximum cross-sectional area, GGN status, nodule boundary and relationship with blood vessels (P < 0.05). The results of ROC curve showed that the AUC value of nodule site and nodule boundary was greater than 0.5, and the nodule boundary AUC value was 0.676, which was more sensitive to predict whether GGN deteriorated to lung adenocarcinoma (LUAD).Conclusion: Nodule site and nodule boundary are effective risk predictors for LUAD in patients with GGN, and nodule boundary is the most valuable independent predictor.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1084-1091"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: PPM1F regulates ovarian cancer progression by affecting the dephosphorylation of ITGB1. 更正：PPM1F 通过影响 ITGB1 的去磷酸化调节卵巢癌的进展。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 DOI: 10.1007/s12094-024-03741-9

Yahui Leng, Zhenzi Luan, Zihang Li, Yongqing Ma, Yang Zhou, Jiaqi Liu, Song Liu, Tian Tian, Wenxiao Feng, Yanni Liu, Qin Shi, Chengyang Huang, Xuan Zhao, Wenlong Wang, Ao Liu, Tianhang Wang, Qiulei Ren, Jiakun Liu, Qian Huang, Yaling Zhang, Bin Yin, Jialin Chen, Liangliang Yang, Shiyun Zhao, Ruoyi Bao, Xingyu Ji, Yuewen Xu, Liaoyuan Liu, Junsuo Zhou, Miao Chen, Wenhui Ma, Li Shen, Te Zhang, Hongyan Zhao

引用次数: 0

Tumor-exosomal miR-205-5p as a diagnostic biomarker for colorectal cancer. 作为结直肠癌诊断生物标志物的肿瘤外泌体 miR-205-5p。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-12 DOI: 10.1007/s12094-024-03647-6

Yajing Zhao, Yapeng Zhao, Lisheng Liu, Guanghao Li, Yawen Wu, Yanan Cui, Li Xie

{"title":"Tumor-exosomal miR-205-5p as a diagnostic biomarker for colorectal cancer.","authors":"Yajing Zhao, Yapeng Zhao, Lisheng Liu, Guanghao Li, Yawen Wu, Yanan Cui, Li Xie","doi":"10.1007/s12094-024-03647-6","DOIUrl":"10.1007/s12094-024-03647-6","url":null,"abstract":"Background: Tumor-derived exosomal miRNAs play crucial roles in cancer diagnosis. Current studies aim to identify exosomal miRNAs associated with colorectal cancer (CRC) that are noninvasive, sensitive, and specific.Patients and methods: Exosomes were extracted from CRC patients and healthy donors via ultracentrifugation, followed by verification via transmission electron microscopy (TEM), qNano, and Western blot analysis. The differential expression levels and clinical characteristics of miR-205-5p were analyzed in CRC via data from The Cancer Genome Atlas (TCGA). Real-time quantitative PCR was used to assess the expression levels of exosomal miRNAs in 157 primary CRC patients, 20 patients with benign diseases, and 135 healthy donors. Predictions regarding target genes were made to guide further exploration of the disease's etiopathogenesis through bioinformatics.Results: Compared with that in healthy donors, the expression of miR-205-5p in colorectal cancer (CRC) patients was significantly lower, as determined through analysis of the TCGA database. We conducted a prediction and analysis of the functional enrichment of downstream target genes regulated by miR-205-5p. A lower level of exosomal miR-205-5p in the serum of CRC patients than in that of healthy controls (p < 0.0001) and patients with benign disease (p < 0.0001) was observed. Furthermore, the expression levels of exosomal miR-205-5p were significantly lower in early-stage CRC patients than in the comparison groups (p<0.001 and p < 0.0001). Notably, the expression levels of exosomal miR-205-5p significantly increased postoperatively (p = 0.0053).Conclusions: The present study demonstrated that serum exosomal miR-205-5p may be a diagnostic biomarker for CRC.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1185-1197"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study.

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-02-28 DOI: 10.1007/s12094-025-03866-5

Mine İlayda Şengör Aygün, Özben Yalçın

引用次数: 0

Patterns of failure after stereotactic body radiotherapy to non-spine bone metastases. 非脊椎骨转移瘤立体定向体放射治疗失败的模式。

IF 2.8 3区医学

Clinical & Translational Oncology Pub Date : 2025-02-26 DOI: 10.1007/s12094-025-03878-1

Héctor Pérez-Montero, Alicia Lozano, Rodolfo de Blas, Javier Hernández, Arantxa Mera, Ferrán Guedea, Arturo Navarro-Martín

{"title":"Patterns of failure after stereotactic body radiotherapy to non-spine bone metastases.","authors":"Héctor Pérez-Montero, Alicia Lozano, Rodolfo de Blas, Javier Hernández, Arantxa Mera, Ferrán Guedea, Arturo Navarro-Martín","doi":"10.1007/s12094-025-03878-1","DOIUrl":"https://doi.org/10.1007/s12094-025-03878-1","url":null,"abstract":"Background and purpose: Stereotactic body radiotherapy (SBRT) has proven useful for non-spine bone metastases (NSBM). We analyzed local relapse rates and patterns of failure after NSBM-SBRT, contrasting our results with existing contouring guidelines.Materials and methods: We conducted a retrospective analysis of NSBM-SBRT treatments performed between 2013 and 2024 in a single institution. Clinical, pathologic, and treatment-related data were collected. Failure patterns were assessed based on imaging tests and categorized as in-field, marginal/out-of-field.Results: Among 119 NSBM-SBRT treatments in 85 patients, the most common primary tumors were prostate (36.1%) and breast cancer (24.4%). The coxal bone was the predominant metastatic site (52.9%). The median follow-up was 32.8 months. OS rates at 1, 2, and 3 years were 90.1%, 83.5%, and 75.8%, respectively. Twenty seven relapses were observed in the treated bone with a median recurrent tumor volume of 9.9 cm3 and a median time to recurrence of 15.1 months. Relapse-free survival in the treated bone was 89.4%, 78.5%, and 74.2% at 1, 2, and 3 years, respectively. Median recurrent tumor volume within the CTV was 50.6% and the median distance from the relapse center to the initial tumor was 11.4 mm.Conclusion: NSBM-SBRT provides effective local control with relapses often occurring near the initial tumor lesion. While adherence to existing contouring guidelines captures most scenarios, consideration of larger CTV expansions may be warranted in cases with poorer prognosis. Further studies are needed to identify risk factors for relapses outside the margins and optimize volume delineation in these scenarios.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0